Daytrana® is a medicinal patch developed and marketed by Noven Pharmaceuticals, Inc. that was approved in April 2006. In the literature, Daytrana® is most commonly referred to as MethylphenidateTransdermal System (MTS).
Daytrana is approved by the U.S. Food and Drug Administration (FDA) as a once daily treatment of pediatric patients—ages 6 to 17—with attention deficit hyperactivity disorder (ADHD). However, off-label prescriptions in older patients are not uncommon. It is mainly prescribed as a second-line treatment for ADHD when traditional oral forms are not well-tolerated or if patients have difficulty with compliance.
Noven's original FDA submission indicated that it should be used for 12 hours; when the FDA rejected the submission they requested evidence that a shorter time period was safe and effective; Noven provided such evidence and Daytrana® was approved for the aforementioned indication over a 9 hour period.
Unlike with transdermal administration, orally administered methylphenidate is subject to first-pass metabolism, by which the levo-isomer is extensively metabolized. By circumvention of this first-pass metabolism the relative concentrations of l-threo-methylphenidate are much higher with transdermal administration (50-60% of those of dexmethylphenidate instead of about 14-27%).  Because the d-enantiomer is pharmacologically the most active one by far, this is of limited importance.
^Heal DJ, Pierce DM (2006). "Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system". CNS Drugs20 (9): 713–738 (Page:730). doi:10.2165/00023210-200620090-00002. PMID16953648.